Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced Cancer × IDO-1 inhibitor LY3381916 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Cytopenia 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Cancer 1

Interventions

Nivolumab 20 Ipilimumab 10 Paclitaxel 7 linrodostat 6 Standard of Care 6 Sirolimus 5 Gemcitabine 5 Bevacizumab 5 temsirolimus 4 relatlimab 4 Pemetrexed 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Vorinostat 3 Erlotinib Hydrochloride 3 Dasatinib 3 Cetuximab 3 regorafenib 2 olaparib 2 apatinib 2 anlotinib 2 abemaciclib 2 Trastuzumab 2 Surveys and Questionnaires 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡